Golden State Equity Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Golden State Equity Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-476	Closed	-$368K	–	1427
2026 Q1	$368K	Buy	476 +121	+34%	+$92.6K	0.03%	528
2025 Q4	$274K	Sell	355 -591	-62%	-$401K	0.04%	417
2025 Q3	$532K	Buy	946 +71	+8%	+$40.1K	0.09%	247
2025 Q2	$459K	Sell	875 -571	-39%	-$319K	0.09%	260
2025 Q1	$917K	Buy	1,446 +88	+6%	+$60.5K	0.18%	141
2024 Q4	$967K	Buy	1,358 +1,272	+1,479%	+$1.07M	0.18%	134
2024 Q3	$90.4K	Buy	+86	New	+$95.7K	0.01%	480
2021 Q3	–	Sell	-558	Closed	-$312K	–	273
2021 Q2	$312K	Buy	+558	New	+$283K	0.12%	172

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Golden State Equity Partners's REGN Position: Q2 2026 in Review

Golden State Equity Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 476 shares — an estimated $368K sold.

Golden State Equity Partners first reported a position in REGN in Q2 2021 and held it in 8 quarters. The position peaked at $967K in Q4 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Golden State Equity Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Golden State Equity Partners sold 476 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $368K.
Golden State Equity Partners first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 8 quarters.
Golden State Equity Partners's Regeneron Pharmaceuticals position peaked at $967K in Q4 2024.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.